Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial (vol 20, pg 408, 2019)

Smith M.; Parker C.; Saad F.

首页> 外文期刊>The lancet oncology >Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial (vol 20, pg 408, 2019)

【24h】

Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial (vol 20, pg 408, 2019)

机译：在抗阉割前列腺癌和骨转移患者中添加镭的醋酸盐和泼尼松或泼尼松酮（ERA 223）：随机，双盲，安慰剂控制，第3期试验（Vol 20，PG 408,2019 的）

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The lancet oncology》 |2019年第10期|共1页
作者
Smith M.; Parker C.; Saad F.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial (vol 20, pg 408, 2019) [J] . Smith M., Parker C., Saad F. The lancet oncology . 2019,第10期

机译：在抗阉割前列腺癌和骨转移患者中添加镭的醋酸盐和泼尼松或泼尼松酮（ERA 223）：随机，双盲，安慰剂控制，第3期试验（Vol 20，PG 408,2019 的）
2. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial [J] . Smith Matthew, Parker Chris, Saad Fred, The lancet oncology . 2019,第3期

机译：在抗阉割的前列腺癌和骨转移患者中添加镭-223至Abiraatorone醋酸盐和泼尼松或泼尼松龙（ERA 223）：A随机，双盲，安慰剂控制，第3期试验
3. Re: Addition of Radium-223 to Abiraterone Acetate and Prednisone or Prednisolone in Patients with Castration-resistant Prostate Cancer and Bone Metastases (ERA 223): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial [J] . van der Poel Henk European urology . 2019,第5期

机译：Re：向抗阉割前列腺癌和骨转移患者中添加镭酮和泼尼松或泼尼松龙（ERA 223）：随机，双盲，安慰剂，第3期试验
4. Phase I trial of motexafin-lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate cancer [C] . Diana C. Stripp, Rosemarie Mick, Timothy C. Zhu, Conference on optical methods for tumor treatment and detection: Mechanisms and techniques in photodynamic therapy . 2004

机译：Matexafin-Lutetium介导的患者局部复发前列腺癌患者的术语I阶段试验
5. A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide [O] . D.P. Petrylak, U.N. Vaishampayan, K.R. Patel, 2021

机译：含镭-223二氯化钠或与AbiraTerone醋酸盐/泼尼松或苯甲酸丁酰胺组合处理的转移阉割抗性前列腺癌（MCRPC）的量化骨扫描响应的随机相IIA研究
6. A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide [O] . D.P. Petrylak, U.N. Vaishampayan, K.R. Patel, 2021

机译：含镭-223二氯化钠或与AbiraTerone醋酸盐/泼尼松或苯甲酸丁酰胺组合处理的转移阉割抗性前列腺癌（MCRPC）的量化骨扫描响应的随机相IIA研究

Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial (vol 20, pg 408, 2019)

著录项

相似文献

相关主题

期刊订阅